TY - JOUR
T1 - The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension
T2 - a multicenter randomized-controlled trial; MUSCAT-3 study
AU - Umebayashi, Ryoko
AU - Uchida, Haruhito Adam
AU - Okuyama, Yuka
AU - Kakio, Yuki
AU - Hanayama, Yoshihisa
AU - Shikata, Kenichi
AU - Wada, Jun
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.
AB - Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.
KW - albuminuria
KW - Angiotensin II receptor blocker
KW - hypertension
KW - inflammation
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85057585448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057585448&partnerID=8YFLogxK
U2 - 10.1080/1354750X.2018.1548033
DO - 10.1080/1354750X.2018.1548033
M3 - Article
C2 - 30444137
AN - SCOPUS:85057585448
JO - Biomarkers
JF - Biomarkers
SN - 1354-750X
ER -